Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma

References

• Swerdlow S, Campo E, Pileri S, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris N, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
   Google Scholar
• Slack GW, Gascoyne RD. MYC and aggressive B-cell lymphomas. Adv Anat Pathol. 2011;18:219–228.10.1097/PAP.0b013e3182169948
   PubMed Web of Science ®Google Scholar
• Bürgesser MV, Gualco G, Diller A, et al. Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina. Ann Diagn Pathol. 2013;17:250–255.10.1016/j.anndiagpath.2012.11.001
   PubMed Web of Science ®Google Scholar
• Lin P, Dickason TJ, Fayad LE, et al. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer. 2012;118:1566–1573.10.1002/cncr.v118.6
   PubMed Web of Science ®Google Scholar
• Perry AM, Crockett D, Dave BJ, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. Br J Haematol. 2013;162:40–49.10.1111/bjh.2013.162.issue-1
   PubMed Web of Science ®Google Scholar
• Corazzelli G, Frigeri F, Russo F, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and ‘unclassifiable’ highly aggressive B-cell lymphoma. Br J Haematol. 2012;156:234–244.10.1111/bjh.2011.156.issue-2
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Johnson JL, Byrd JC, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol. 2014;165:102–111.10.1111/bjh.2014.165.issue-1
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology non-Hodgkin’s lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood. 1999;94:33–38.
   PubMed Web of Science ®Google Scholar
• Ishii K, Urase F, Nagare Y, et al. VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: A multicenter experience. Arch Gerontol Geriatr. 2010;51:209–215.10.1016/j.archger.2009.10.010
   PubMed Web of Science ®Google Scholar
• Fina M, Tani M, Stefoni V, et al. VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. Leuk Lymphoma. 2007;48:2167–2171.10.1080/10428190701642102
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.10.1182/blood-2003-05-1545
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3452–3459.10.1200/JCO.2011.41.0985
   PubMed Web of Science ®Google Scholar
• Staiger AM, Ziepert M, Horn H, et al. Clinical impact of the cell-of-origin classification and the MYC/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German high-grade non-Hodgkin‘s Lymphoma study group. J Clin Oncol. 2017;35:2515–2526.10.1200/JCO.2016.70.3660
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Kobayashi Y, Maeshima AM, et al. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Int J Hematol. 2016;103:693–702.10.1007/s12185-016-1989-z
   PubMed Web of Science ®Google Scholar
• Selvi SK, Kar R, Basu D, et al. Clinicopathological analysis of B Cell lymphomas, unclassifiable; with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in a Tertiary Care Hospital in Southern India. Indian J Hematol Blood Transfus. 2016;32:168–175.10.1007/s12288-015-0558-6
   PubMed Web of Science ®Google Scholar
• Fabbri A, Cencini E, Rigacci L, et al. Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma. 2014;55:781–785.10.3109/10428194.2013.826354
   PubMed Web of Science ®Google Scholar
• Fabbri A, Cencini E, Bocchia M. Treatment decisions and outcome in very elderly patients with diffuse large B-Cell lymphoma. Cancer. 2015;121:3746–3747.10.1002/cncr.29509
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–1861. PMID:17244675.10.1182/blood-2006-08-038257
   PubMed Web of Science ®Google Scholar
• Cox MC, Di Napoli A, Scarpino S, et al. Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component. Plos One. 2014;9:e93903.10.1371/journal.pone.0093903
   PubMed Web of Science ®Google Scholar
• Tonelli S, Capitelli M, Fontana MC, et al. Primary cardiac diffuse large B-cell lymphoma in a elderly patient. A case report. Haematologica. 2017;102(s3):164.
   Google Scholar
• Lynch RC, Gratzinger D, Advani RH. Clinical impact of the 2016 update to the WHO lymphoma classification. Curr Treat Options Oncol. 2017;18(11):2375.10.1007/s11864-017-0483-z
   Google Scholar
• Ott, G. Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings. Br J Haematol. 2017;178:871–887.10.1111/bjh.2017.178.issue-6
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L. The 2016 updated WHO classification of lymphoid neoplasias. Hematol Oncol. 2017;35:37–45.10.1002/hon.2399
   PubMed Web of Science ®Google Scholar